The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for HIV-1 drug candidate Biktarvy.

Biktarvy is a combination of 50mg bictegravir, 200mg emtricitabine and 25mg tenofovir alafenamide (BIC/FTC/TAF).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Bictegravir is an integrase strand transfer inhibitor, and the combination of emtricitabine and tenofovir alafenamide is a dual nucleoside reverse transcriptase inhibitor.

In the MAA, the company is seeking approval for Biktarvy as a once-daily single tablet regimen for adults who do not have any present or past evidence of viral resistance to emtricitabine or tenofovir alafenamide.

The MAA includes results from four separate ongoing Phase III clinical trials, two involving treatment-naïve patients, and two involving virologically suppressed subjects. A total of 2,415 adult participated in the trials.

“Triple therapy has been the standard of HIV treatment for more than 20 years and has allowed people living with HIV to achieve durable undetectability.”

The trials are reported to have met the primary objective of non-inferiority at 48 weeks.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Gilead Sciences chief medical officer Andrew Cheng said: “Triple therapy has been the standard of HIV treatment for more than 20 years and has allowed people living with HIV to achieve durable undetectability.

“At Gilead, we have continued to explore ways to improve and provide more HIV treatment options, with the goal of going beyond reducing viral load and helping to address some of the wider challenges faced by people living with HIV.”

Cheng added that if approved, Biktarvy will be the fifth TAF-based product for HIV approved in the EU in the last three years.

The drug interaction profile, minimal monitoring requirements and ease of administration represent a meaningful advance in HIV treatment in Europe.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact